Jpmorgan Chase & CO Cidara Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.64 - $0.92 $629 - $904	-983 Reduced 68.55%	451 $0
Q4 2023 Feb 12, 2024	BUY	$0.68 - $0.97 $748 - $1,067	1,100 Added 329.34%	1,434 $1,000
Q3 2023 Nov 14, 2023	SELL	$0.77 - $1.16 $36 - $55	-48 Reduced 12.57%	334 $0
Q2 2023 Aug 11, 2023	BUY	$1.01 - $1.42 $262 - $369	260 Added 213.11%	382 $0
Q1 2023 May 11, 2023	SELL	$0.75 - $1.98 $66 - $174	-88 Reduced 41.9%	122 $0
Q4 2022 Feb 13, 2023	SELL	$0.48 - $13.08 $15 - $431	-33 Reduced 13.58%	210 $0
Q3 2022 Nov 14, 2022	BUY	$0.45 - $13.0 $14 - $429	33 Added 15.71%	243 $0
Q2 2022 Aug 11, 2022	BUY	$0.43 - $0.91 $37 - $80	88 Added 72.13%	210 $0
Q1 2022 May 11, 2022	SELL	$0.67 - $1.39 $6,763 - $14,032	-10,095 Reduced 98.81%	122 $0
Q4 2021 Feb 10, 2022	BUY	$1.18 - $2.18 $9,036 - $16,694	7,658 Added 299.26%	10,217 $13,000
Q3 2021 Nov 12, 2021	BUY	$1.48 - $2.35 $3,787 - $6,013	2,559 New	2,559 $5,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.24B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.